Phase 3 Safety and Efficacy Study of Rolapitant for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Subjects Receiving Highly Emetogenic Chemotherapy (HEC)
This study is currently recruiting participants.
Verified October 2012 by Tesaro, Inc.
Study NCT01499849
Information provided by Tesaro, Inc.
First Received on December 20, 2011.
Last Updated on October 24, 2012
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
